Fas ligand as a tool for immunosuppression and generation of immune tolerance.
The role of Fas ligand (FasL) in physiologically limiting immune responses and maintaining immune-privileged sites has led to a body of research aiming to confer protection to allogeneic grafts by expressing FasL on the allogeneic tissue or by administrating FasL-transduced donor dendritic cells. In addition, several studies have used FasL to abrogate autoimmune responses. This review presents the results of these studies and discusses the problems associated with FasL usage.
Bohana-Kashtan
Osnat
O
Department of Oncology, Immunology and Hematopoiesis Division, Sidney Kimmel Comprehensive Cancer at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA.
Civin
Curt I
CI
D000818:Animals; D019070:Cell Lineage; D017690:Cell Transplantation; D003713:Dendritic Cells / Q000166:cytology; D053222:Fas Ligand Protein; D006801:Humans; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008562:Membrane Glycoproteins / Q000502:physiology*; D014180:Transplantation / Q000379:methods*; D014184:Transplantation, Homologous
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007166:Immunosuppressive Agents; D008562:Membrane Glycoproteins